Navigation Links
Excel Life Sciences Joins DATATRAK's Connect Partner Program
Date:1/25/2012

CLEVELAND, Jan. 25, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the newest member of its Connect Partner Program, Excel Life Sciences (ELS). Excel Life Sciences is a leading US-based, India-operating provider of comprehensive clinical trial and site management services.

"Excel Life Sciences is committed to providing our biopharmaceutical company clients with extraordinary clinical trial management performance and the highest data quality and integrity for their global trials in India," remarked Dan McDonald, Excel Life Sciences SVP of Business Strategy. "In joining the Connect Partner Program, we renew this commitment by offering our clients access to DATATRAK's leading eClinical Solutions and Consulting Services. Excel Life Sciences is proud to announce this new partnership and is excited about the future of working with DATATRAK to meet our clients' evolving needs."

"We are thrilled about Excel Life Sciences joining the DATATRAK Connect Partner Program," stated Dr. Bill Gluck, VP DATATRAK Clinical and Consulting Services™.  "The partnership will assist both companies in reaching their goal of providing the most innovative clinical trial solutions throughout the industry. The level of experience, passion and commitment in producing the highest quality solutions makes this an invaluable partnership."

About Excel Life Sciences
Headquartered in Chicago, IL with offices in Boston, Raleigh-Durham, New Delhi (India HQ) and Kolkata and 17 other locations across India, ELS is one of the most experienced and fastest growing trial management and site support organizations in India, offering customized clinical trial solutions including: regulatory consulting, preparations, submissions and query resolution; site identification and selection; patient recruitment and retention; training of all clinical research stakeholders; technology transfer; product licensing and more.

ELS has one of the most experienced and respected clinical operations teams in India with over 280 years of collective experience in conducting more than 350 global and domestic trials at hundreds of sites and with thousands of patients. ELS has also trained over 1,500 clinical research personnel in India. For more information visit: www.excellifesciences.com.

About DATATRAK 
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending September 30, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
2. 1 Award Winner and 9 Prize Winners in the EFQM Business Excellence Awards
3. Pevions Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
4. Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments
5. EMG Laboratory Attains Prestigious National Accreditation for Clinical Excellence in Neuromuscular Diagnosis
6. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
7. NYU-Poly VP Ubell Recognized for Excellence in Online Learning
8. Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO"
9. LasikPlus® Research Reveals Excellent Results From Modern LASIK
10. American Botanical Council Announces Recipients of Botanical Excellence Awards
11. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):